Background: Heparan sulfate proteoglycans are one of the major components of extracellular matrix and are secreted at different levels by several normal and tumoral cells. Perlecan, the basement membrane proteoglycan, has structural domains involved in cell/matrix interactions and growth factor storage. Metastatic melanoma cells show an increase in perlecan expression as compared to low metastatic ones. We examined whether reduction of perlecan expression could down-modulate the malignant phenotype in melanoma clones.
Introduction
Perlecan is the heparan sulfate of the basement membrane that is typically associated with the extracellular matrix and has structural and biological properties [1, 2] . Perlecan is synthesized by various proliferating cell types. Structurally, it consists of a large 400 kD core protein linked to three heparan sulfate side chains [3] . The complete structure comprises five different domains, which suggests its involvement in several biological functions [3, 4] .
Many heparin binding growth factors (HBGF) require heparin or heparan sulfates for presentation to their receptors and receptor signalling [5] [6] [7] [8] [9] . Of the many heparan sulfates produced by fibroblasts, perlecan has been found to be the most effective at bFGF presentation to surface receptors [10, 11] . In contrast, over-expression of another heparan sulfate proteoglycan, syndecan, actually inhibits bFGF function [12, 13] . Thus perlecan could increase both growth factor accumulation and receptor presentation, in turn stimulating tumour growth and angiogenesis.
Metastasis [14] is a complex sequence of events which includes migration to, adhesion, invasion and subsequent proliferation of tumour cells in a distant organ in the body. Autocrine loops involving growth factors probably contribute to the migratory and invasive phenotype of metastatic cells. We had observed that highly metastatic variants of murine melanoma cells express higher levels of perlecan than low or non metastatic variants [15, 16] . A significant increase in perlecan expression in human invasive melanoma has also been reported [17] . Stable expression of an antisense perlecan cDNA significantly reduces binding of bFGF to its receptor on fibroblasts or melanoma cells without addition of exogenous heparan sulfate, further demonstrating the key role played by perlecan in this process [18] . Melanoma cells have been found to express high levels of bFGF, which could be important in their malignant behavior [19] . In the present study, we have investigated the effects of down-modulation of perlecan in B16-F10, a highly metastatic murine melanoma cell line, using this antisense approach. B16-F10 cells were transfected with a construct containing expressing high levels of an anti-sense cDNA for perlecan. The transfected cells were characterized by evaluation of DNA, mRNA and perlecan protein expression. Several anti-sense perlecan transfected clones showed decreased expression of perlecan as compared to untransfected cells in immunoblot analysis, this corresponded to a reduction of cell growth, migration and invasiveness in these cells.
Materials and methods

Cell culture and transfection
The B16-F10 cell line originally developed by I. J. Fidler and selected for its ability to colonize the lung after Lv. administration (high metastatic ability) was the kind gift of Dr. R. Giavazzi (Istituto Mario Negri, Milan). Wild type cells were maintained in Dulbecco's modified Eagles medium (DMEM, seromed) containing 10% v/v foetal calf serum (FCS, ICN), 1% v/v non-essential ammo acids (PAA), 1% v/v sodium pyruvate (PAA) and 2% v/v mem-vitamins (seromed). 5 x 10 5 cells were seeded, 24 hours prior to transfection, onto 10 cm diameter petri dishes (Becton Dickinson) and maintained in complete DMEM. Transfection was earned out in duplicate using the calcium phosphate co-precipitation method, using 20 ug of phenol xhloroform purified plasmid DNA. The pBAAP plasmid was derived from the pHpAP-1-neo plasmid [20] which can direct high level antisense expression [20] . For controls the pH[3AP-l-neo vector alone was used, for anti-sense transfection, the pBAAP construct containing anti-sense perlecan cDNA [18] was utilized. Individual clones showing geneticin (G418, Calbiochem or Gibco) resistance were selected and expanded in vitro. Transfected clones were maintained and propagated in complete DMEM containing 1.2 mg/ml w/v G418.
Southern blot analysis DNA (10 mg) prepared from transfected and untransfected B16-F10 cells by phenolxhloroform extraction was digested with the restriction enzymes Bg] II and Sma I (Gibco BRL). After heating for 5 minutes at 56 °C, DNA samples were run on a 7% agarose (IBI Inc.) gel and Southern blotted onto nitrocellulose (Schleicher and Schuell) using standard protocols. A 3 Kb fragment encoding the neo resistance gene was isolated by digestion of the pHf3AP-l-neo vector (as used in cell transfection) with Bgl II and Sma I. This insert was used as a probe for the Southern blot analysis of the digested cell DNA to verify stable incorporation of the transfected DNA. As a positive control, 5 pg of pHpAP-1-neo plasmid DNA also cut with Bgl II and Sma I was used.
Northern blot analysis
Northern blot analysis was earned out on RNA isolated from transfected and untransfected B16-F10 cells by the method of Chomzinsky and Sacchi [21] . For Northern hybridization, 20 ug total RNA was electrophoresed on 0.7% agarose gel containing formaldehyde. The gel was then stained with ethidium bromide, destained and transferred to a nitrocellulose filter. Hybridization was performed using a 1.3 Kb perlecan cDNA 32 P-labelled probe [3] Immunoblot analysis
Transfected and untransfected B16-F10 cells at subconfluence were incubated for 24 hours in DMEM without FCS. The resulting conditioned medium was collected and assayed for total protein content using the Bradford Dye Reagent method (BioRad). Lyophilized aliquots of conditioned medium containing between 3.125 and 0.0475 mg protein were re-suspended in Tris buffered saline (10 mm Tris pH 7.4,150 mm NaCl). Samples were spotted manually and adsorbed onto nitrocellulose. After blocking non-specific binding sites for 1 hour at room temperature in agitation in Tris buffered salme containing 2% w/v bovine serum albumin (BSA, Sigma Chemical Co.), the blot was incubated for 1 hour at room temperature with an anti-perlecan antibody (1:1000 dilution inTris/BSA) kindly provided by Prof. J. Hassell (Department of Ophthalmology, University of Pittsburgh, USA). Subsequently, the blot was washed three times with Tris buffered saline containing 0.5% v/vTween 20 (Sigma Chemical Co.). Positive signals were detected by ECL (Amersham Life Science) and visualized by fluorography. Quantitative evaluation of protein spots was performed by densitometric analysis (NIH Image).
Cell proliferation assays
Transfected and untransfected B16-F10 cells were grown in 24 well (10 5 cells/well) plates in complete culture medium for 24 hours. Cells were then incubated with DMEM containing 10% FCS or 0.1 ng/ml heparin (ICN Biochemicals) in 0.1% FCS, or 1 ng/ml bFGF (Becton Dickinson) in 0.1% FCS. Cell growth was assed either by directs counts of trypsinized cells with a haemocytometer or by the metabolic MTT assay [22] at 24-hour periods over four consecutive days.
Chemotaxis and cbemoinvasion assays
Transfected and untransfected B16-F10 cells (1.5 x 10 5 cells) were seeded in serum-free DMEM containing 0.1% BSA onto a PVP-free polycarbonate filter (Nucleopore, Concorezzo, Milan) in a modified Boyden chamber. For chemotaxis, the filters were coated with gelatin and for chemoinvasion the filters were coated with 50 ug matrigel (a reconstituted basement membrane from the EHS tumour [23] ). As a chemoattractant in the lower compartment of the Boyden chamber, either serum-free DMEM containing 0.1% w/v BSA or conditioned medium from NIH 3T3 (NIH-CM) fibroblast cells were used. After six hours incubation at 37 °C, 5% CO2, cells remaining on the upper surface of the filter were mechanically removed and those on the under-surface were fixed and quantitated microscopically after staining with 2% w/v Toluidine blue (Sigma Chemical Co.). Assays were carried out in triplicate and repeated twice.
Experimental lung metastasis assay
The metastatic potential of the B16F10 parental cells and transfectants was determined using an experimental metastasis assay. Cells were counted in trypan blue to exclude counting any damaged cells and they were i.v. injected (5 x 10 4 live cells per animal) mto the tail vein of seven-week-old female nu/nu (athymic) mice. Twelve animals for each experimental group were used. After three weeks mice were sacrificed, the lungs of the animals were removed, washed with PBS, weighed and fixed in formalin. Lung weights correlated with the number of metastases, and was used for accurate determination total metastasis burden in the lung.
Results
Expression of perlecan anti-sense cDNA in B16-F10 murine melanoma cells
B16-F10 murine melanoma cells were transfected with the expression vector pBAAP containing a 1.3 Kb perlecan cDNA in the anti-sense direction [18] under the control of the p-actin promoter [20] . Several geneticin resistant clones were isolated and five, designated Anti-P 1, Anti-P 2, Anti-P 11, Anti-P 13 and Anti-P 14, and the pHpAP-1-neo control showed the characteristic band for the transfected neo resistance gene in southern blot analysis (Figure 1 ). In contrast, wild type B16-F10 cells were negative. Northern blot analysis with the same cDNA used for the antisense expression demonstrated the high levels of perlecan antisense mRNA in the selected clones (Figure 2 ), while wild type and control transfectants were negative.
Perlecan levels in engineered cells
Conditioned medium from both wild type and transfected B16-F10 cells was tested in an immunoblot assay using an affinity purified polyclonal antibody preparation against mouse perlecan. Antibody reactivity with serial dilutions of secreted protein demonstrated reduced protein production by transfectants as compared to the wild type and control transfectants ( Figure 3 )
Effect of anti-sense perlecan expression on cell proliferation
One of the characteristics of a malignant phenotype is the ability to proliferate in the absence of growth factors. We have analyzed the proliferation of our transfectants in respect to the wild type cell line when cultured in a low (0,1%) serum concentration. While the proliferation rate of B16-F10 and control transfectants was not affected by serum deprivation, the proliferation of the perlecan antisense clones was strongly reduced ( Figure  4a ). In the presence of complete medium (10% FCS) a similar proliferative rate for the wild type and the transfected cells was observed (Figure 4b ). Parental B16-F10 cells showed rapid proliferation in low serum (0.1%) supplemented with bFGF. In contrast, the perlecan antisense transfected clones showed reduced proliferation in response to bFGF (Figure 4c ).
Anti-sense perlecan expression reduced the migratory and invasive properties of B16-F10 cells
Other key characteristics of malignant cells are the ability to migrate and invade into surrounding tissues and distant organs. We therefore compared the migratory and invasive activity of perlecan antisense transfectants with the parental and control transfectants using in vitro assays based on Boyden chambers [24, 25] . The anti-sense perlecan clones showed a 50% reduced invasion in response to the NIH-CM used as chemoattractant when compared to the wild type and vectoralone transfected B16-F10 cells (Figure 5a ). Chemotaxis of these same cells was less dramatically effected ( Figure  5b ), suggesting that alteration of perlecan expression changes the invasive capacity of the malignant cells. This was confirmed in vivo in the experimental metastasis assay. Antisense perlecan transfected clone two cells showed reduced lung metastases burden (363 ± 169 mg) as compared to control Neo transfected cells (606 ± 330 mg), P < 0.05 using Student's Mest.
Conclusions
Perlecan, the basement membrane proteoglycan, is expressed at different levels in normal and tumor tissue. Perlecan is abundant in liver neoplastic nodules and a 20-fold increase in glycosaminoglycan content has been observed in malignant tissue in comparison to that in normal liver [26] . Human and murine metastatic melanomas express high levels of perlecan [15] [16] [17] . We have previously demonstrated that down modulation of perlecan by antisense constructs inhibits bFGF-induced proliferation of NIH 3T3 and human melanoma cells by interfering with the interactions of bFGF with its receptor [18] . In this study, we have investigated the effects of perlecan reduction on the biological properties associated with malignancy in murine melanoma cells. Stable over-expression of perlecan antisense cDNA in B16-F10 murine melanoma cells reduced perlecan protein production and concomitantly the ability of these cells to grow in the absence of exogenous growth factors including bFGF, and the invasive potential of melanoma cells. The effects of perlecan reduction are most likely mediated by interruption of the autocrine growth factor-growth factor receptor interactions in these tumor cells. Perlecan is clearly important in regulating bFGFreceptor interactions [10, 11, 18] , and bFGF appears to be an important growth factor for human melanoma [19] . However, perlecan could also regulate the interaction of a number of heparin-binding growth factors with their receptors which could contribute to the effects of perlecan suppression. The increase of perlecan expression in murine and human melanoma [15] [16] [17] and in some other neoplasms [26] most likely serves to increase the response of these cells to autocrine and paracrine growth factors.
The role of perlecan in regulating growth factor responses has also been exploited in normal physiological processes. A shift in perlecan synthesis regulates the shift from aFGF to bFGF responsiveness in developing neural cells [27] . A similar regulation of bFGF response by perlecan expression occurs in cultured retinal pigment cells [28] . The induction of neovascular formation by growing tumor cells, tumor angiogenesis, appears to be regulated by heparin binding growth factors, in particular bFGF and VEGF [29, 30] . Both VEGF and bFGF are dependent upon heparan sulfates for receptor signalling, thus localized perlecan reduction could significantly inhibit tumor induced angiogenesis as well.
This study indicates that interference with autocrine growth factor loops which are dependent on perlecan could reduce the malignant potential of certain neoplasms. This raises the possibility of using perlecan antisense approaches in gene therapy approaches to management of cancer.
